Identification

Brand Name
Herceptin
Product Description
Herceptin is a prescription HER2 receptor antagonist available in multiple countries including the United States, Canada, the EU, Italy, and Indonesia. It was first marketed in 1998. It is available in an Intravenous Injection and a Subcutaneous Injection. It contains one active ingredient: Trastuzumab. Trastuzumab is an injectable medication used to treat certain types of cancers that overexpress the HER2 protein.
Ingredients
DrugSalt
TrastuzumabNot Available

Pharmacology

Indications
Treatment of Breast Cancer Prescription
Treatment of HER2-Positive Early Stage Breast Cancer Prescription
Treatment of Metastatic Breast Cancer Prescription
Treatment of Metastatic Gastric Adenocarcinoma Prescription
Treatment of Metastatic Gastroesophageal Junction Adenocarcinoma Prescription
Used as adjunct in combination to treat Locally Advanced Breast Cancer (LABC) in a regimen Prescription
Used as adjunct in combination to treat metastatic HER2-positive Adenocarcinoma of the Stomach in a regimen Prescription
Used as adjunct in combination to treat metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction in a regimen Prescription
Used as adjunct in combination to treat unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach in a regimen Prescription
Used as adjunct in combination to treat unresectable, locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction in a regimen Prescription
Used in combination to treat Breast Cancer in a regimen Prescription
Used in combination to treat HER2-Positive Early Stage Breast Cancer in a regimen Prescription
Used in combination to treat Hormone Receptor Positive Metastatic Breast Cancer in a regimen Prescription
Used in combination to treat Inflammatory Breast Cancer (IBC) in a regimen Prescription
Used in combination to treat Locally Advanced Breast Cancer (LABC) in a regimen Prescription
Used in combination to treat Metastatic Adenocarcinoma of the Gastroesophageal Junction in a regimen Prescription
Used in combination to treat Metastatic Adenocarcinoma of the Stomach in a regimen Prescription
Used in combination to treat Metastatic Breast Cancer in a regimen Prescription
Used in combination to treat Metastatic Gastric Adenocarcinoma in a regimen Prescription
Used in combination to treat Metastatic Gastroesophageal Junction Adenocarcinoma in a regimen Prescription
Used in combination to treat Stage I Breast Cancer in a regimen Prescription
Used in combination to treat Unresectable Breast Cancer in a regimen Prescription
Used in combination to treat Wild-type RAS Metastatic Colorectal Cancer in a regimen Prescription
Used in combination to treat unresectable RAS Wild Type Colorectal Cancer in a regimen Prescription
Products
DosageStrengthRouteLabellerMarketing StartMarketing EndNDC Code
Injection, solution600 mgSubcutaneousRoche Registration Gmbh2016-09-08-EU flag EU/1/00/145/003
Injection, solution600 mgSubcutaneousRoche Registration Gmbh2016-09-08-EU flag EU/1/00/145/002
Injection, powder, for solution150 mgIntravenousRoche Registration Gmbh2016-09-08-EU flag EU/1/00/145/001
Injection, powder, for solution440 mgBoehringer Ingelheim2016-10-312025-10-19Indonesia flag DKI1454500144A1
Injection600 MG/5MLParenteralBoehringer Ingelheim2018-05-232023-05-23Indonesia flag DKI1857507343A1
Injection, powder, for solution150 mgIntravenousBoehringer Ingelheim2017-11-212022-11-21Indonesia flag DKI1657507044B1
Injection, powder, lyophilized, for solution150 mg/7.4mLIntravenousGenentech, Inc.2017-02-10-US flag 50242-132
SolutionIntravenous2000-06-29-Mexico flag 202M2000:1
Injection, solution600 MGParenteral; SubcutaneousRoche Registration Gmbh2015-05-23-Italy flag 034949038
Injection, solution600 MG/5MLParenteral; SubcutaneousRoche Registration Gmbh2014-07-08-Italy flag 034949026
Injection, powder, for solution150 MGIntravenousRoche Registration Gmbh2014-07-08-Italy flag 034949014
Powder, for solution440 mg / vialIntravenousHoffmann La Roche1999-08-23-Canada flag 02240692
Injection150 mg/7.4mLIntravenousGenentech, Inc.1998-09-25-US flag 50242-134
420 mg/20mLIntravenousGenentech, Inc.1998-09-25-US flag 50242-333

Interactions